CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

about

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

Item

http://www.wikidata.org/entity/Q36019759

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@ast

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@en

type

Item

label

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@ast

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@en

prefLabel

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@ast

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@en

P1476

CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification

@en

P2093

Chris Fegan

http://www.w3.org/2001/XMLSchema#string

Chris Pepper

http://www.w3.org/2001/XMLSchema#string

Pierre Rizkallah

http://www.w3.org/2001/XMLSchema#string

Reiss A Reid

http://www.w3.org/2001/XMLSchema#string

P2860

Peptide length determines the outcome of TCR/peptide-MHCI engagement

Coot: model-building tools for molecular graphics

Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.

Post-translational modifications of naturally processed MHC-binding epitopes.

Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment

Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

T cells recognizing a peptide contaminant undetectable by mass spectrometry.

JLigand: a graphical tool for the CCP4 template-restraint library.

Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.

P31

scholarly article

P356

10.1111/IMM.12398

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Man

James E Redman

P577

2014-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266399374

http://www.w3.org/2001/XMLSchema#string

P698

25284607

http://www.w3.org/2001/XMLSchema#string

P932

4557686

http://www.w3.org/2001/XMLSchema#string